Navigation Links
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder.

EMSAM previously was marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers. Manufactured by Mylan subsidiary Mylan Technologies Inc. (MTI), EMSAM is a registered trademark of Somerset Pharmaceuticals Inc. In July 2008, Mylan acquired Watson Pharmaceutical Inc.'s 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

Dey President Carolyn Myers, Ph.D., said, "I am very pleased that we have the opportunity to bring the marketing and distribution of EMSAM back into the Mylan family of companies. EMSAM was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward."

Dey, a Mylan company, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. For more information on Dey or its products,
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
4. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
8. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
9. Dental Implant Market Insights Webinar
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  David Hardison, ... ConvergeHEALTH by Deloitte , has been elected chairman ... Standards Consortium, a non-profit working to establish common ... particularly as it relates to electronic health records. ... CDISC,s mission of collaborating with organizations across the ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/28/2014)... The National Model Aviation Museum, located at the ... announce that it has been granted full civilian museum ... Air Force. , The certification is the culmination of ... with an on-site inspection by Sarah Sessions, Museum Certification ... National Museum of the United States Air Force , ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...
... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...
... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2IsoTis Adjourns Special Meeting to October 23, 2007 3IsoTis Adjourns Special Meeting to October 23, 2007 4CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6
(Date:7/28/2014)... The findings of a new study suggest two ways ... not work as well in obese women, compared to women ... are a one-size-fits-all method, researchers say, but as the population ... the pill works for obese women. Studies have consistently found ... the body, which may in turn affect how well the ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are using ... varying flexibility that can be used as microscale models ... that "bead-spring" polymers, introduced as theory in the 1950s, ... required and should be of interest to materials scientists ... work led by Rice chemical and biomolecular engineer Sibani ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Seeing is bead-lieving 2
... 1, 2008, New York, NY) The Parkinson,s Disease Foundation ... its 2008-2009 International Research Grants and Fellowship Program (IRGFP). ... Parkinson,s scientists, chosen on April 11 from a group ... led by Stanley Fahn, M.D., PDF,s Scientific Director. ...
... Technology shows that coating a titanium implant with a ... growth around the implant and strengthens the attachment and ... "We designed a coating that specifically communicates with cells ... the implant," said Andrs Garca, professor and Woodruff Faculty ...
... Crop yield is highly dependent on soil plant-available water, ... up by plant roots. Quantitative determination of the maximum ... on soil samples remains challenging, especially at the scale ... water capacity for a field would be instrumental in ...
Cached Biology News:The Parkinson's Disease Foundation awards $950,000 in seed grants 2The Parkinson's Disease Foundation awards $950,000 in seed grants 3Researchers coat titanium with polymer to improve integration of joint replacements 2Researchers coat titanium with polymer to improve integration of joint replacements 3Where is your soil water? Crop yield has the answer 2
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
BD BaculoGoldTM Transfection Kit 5 transfections...
...
...
Biology Products: